AirSculpt Technologies Past Earnings Performance
Past criteria checks 0/6
AirSculpt Technologies's earnings have been declining at an average annual rate of -39.3%, while the Healthcare industry saw earnings growing at 5.3% annually. Revenues have been growing at an average rate of 24% per year.
Key information
-39.3%
Earnings growth rate
35.1%
EPS growth rate
| Healthcare Industry Growth | 8.5% |
| Revenue growth rate | 24.0% |
| Return on equity | -9.4% |
| Net Margin | -4.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Why Investors Shouldn't Be Surprised By AirSculpt Technologies, Inc.'s (NASDAQ:AIRS) 30% Share Price Surge
Nov 14
Is AirSculpt Technologies (NASDAQ:AIRS) A Risky Investment?
Nov 07The Return Trends At AirSculpt Technologies (NASDAQ:AIRS) Look Promising
Oct 20Optimistic Investors Push AirSculpt Technologies, Inc. (NASDAQ:AIRS) Shares Up 29% But Growth Is Lacking
Sep 28Is It Time To Consider Buying AirSculpt Technologies, Inc. (NASDAQ:AIRS)?
Sep 25The Market Lifts AirSculpt Technologies, Inc. (NASDAQ:AIRS) Shares 26% But It Can Do More
Aug 01There's Been No Shortage Of Growth Recently For AirSculpt Technologies' (NASDAQ:AIRS) Returns On Capital
Apr 04Here's Why AirSculpt Technologies (NASDAQ:AIRS) Can Manage Its Debt Responsibly
Feb 23AirSculpt Technologies, Inc. (NASDAQ:AIRS) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable
Dec 14US$8.19: That's What Analysts Think AirSculpt Technologies, Inc. (NASDAQ:AIRS) Is Worth After Its Latest Results
Nov 12Be Wary Of AirSculpt Technologies (NASDAQ:AIRS) And Its Returns On Capital
Sep 20Capital Allocation Trends At AirSculpt Technologies (NASDAQ:AIRS) Aren't Ideal
Oct 29AirSculpt Technologies: Niche Offering Offset By Profitability, Valuation
Aug 27AirSculpt Technologies reports Q2 earnings beat; reaffirms FY22 guidance
Aug 12Revenue & Expenses Breakdown
How AirSculpt Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 189 | -8 | 108 | 0 |
| 30 Jun 24 | 193 | -3 | 107 | 0 |
| 31 Mar 24 | 198 | 2 | 100 | 0 |
| 31 Dec 23 | 196 | -4 | 108 | 0 |
| 30 Sep 23 | 189 | -7 | 110 | 0 |
| 30 Jun 23 | 181 | -13 | 108 | 0 |
| 31 Mar 23 | 175 | -14 | 106 | 0 |
| 31 Dec 22 | 169 | -15 | 106 | 0 |
| 30 Sep 22 | 166 | -33 | 112 | 0 |
| 30 Jun 22 | 161 | -17 | 100 | 0 |
| 31 Mar 22 | 147 | -8 | 84 | 0 |
| 31 Dec 21 | 133 | 0 | 69 | 0 |
| 30 Sep 21 | 119 | 31 | 41 | 0 |
| 30 Jun 21 | 102 | 25 | 36 | 0 |
| 31 Mar 21 | 78 | 15 | 30 | 0 |
| 31 Dec 20 | 63 | 8 | 26 | 0 |
| 31 Dec 19 | 41 | -2 | 22 | 0 |
Quality Earnings: AIRS is currently unprofitable.
Growing Profit Margin: AIRS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AIRS is unprofitable, and losses have increased over the past 5 years at a rate of 39.3% per year.
Accelerating Growth: Unable to compare AIRS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AIRS is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (10.3%).
Return on Equity
High ROE: AIRS has a negative Return on Equity (-9.44%), as it is currently unprofitable.